SINTX Study Shows Broad Spectrum Antiviral Activity Of Silicon Nitride; Stock Up In Pre-market

(RTTNews) - SINTX Technologies, Inc. (SINT), an advanced ceramics company specializing in biomedical applications of silicon nitride (SiN), Wednesday announced the publication of a study showing that silicon nitride exhibits strong antiviral activity against various infectious virus strains, including SARS-CoV-2 and MERS-CoV. Following the news, the company's shares were more than 20% up in pre-market.

The study, conducted in collaboration with Professor Kylene Kehn-Halls group at Virginia Polytechnic Institute and State University, showed that direct contact to alpha-phase silicon nitride reduced infectious SARS-CoV-2 titers by up to 99.97% within 10 minutes and inactivated completely by 30 minutes. Additionally, 97% inactivation was observed with contact to SiN when embedded in textile fabric widely used in a variety of medical devices and PPE products.

"These results arrive at a time when healthcare systems are actively seeking sustainable solutions to prevent future pandemics, combat antimicrobial resistance, and reduce healthcare-associated infections," said Eric Olson, Chief Executive Officer of SINTX Technologies. "As the only U.S.-based FDA-cleared and ISO-certified silicon nitride manufacturer, we are uniquely positioned to commercialize this technology in high-value markets where safety, efficacy, and scalability matter."

SINTX stock had closed at $4.57, up 10.12% on Tuesday. It has traded in the range of $1.7100 - $8.5960 in the last 1 year.